Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
emaxitinib
- Development stage
- Phase 2
- Lead developer
- Ruishi Biopharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Emaxitinib is an orally administered, highly selective small molecule Janus kinase 1 (JAK1) inhibitor. Developed by Ruishi Biologics, a subsidiary of Hengrui Pharmaceutical, it targets the JAK-STAT signaling pathway, which is involved in inflammatory and immune responses. It is being investigated for the treatment of autoimmune diseases, with a completed Phase III clinical trial for atopic dermatitis.
- Other names
- Ivarmacitinib tablet艾玛昔替尼
02
Targets
Beyond the preview
Go deeper on emaxitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on emaxitinib.